Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference

On September 30, 2021 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, and members of the Mustang Leadership Team will participate in a fireside chat at Chardan’s Virtual 5th Annual Genetic Medicines Conference, taking place on Tuesday, October 5, 2021, at 8:00 a.m. ET (Press release, Mustang Bio, SEP 30, 2021, View Source [SID1234590581]). The company will also participate in one-on-one meetings during the conference. A live webcast of the company’s chat will be available on the Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference

On September 30, 2021 SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, reported that management will be presenting at the Chardan 5th Annual Genetic Medicines Conference on October 4 (Press release, SQZ Biotech, SEP 30, 2021, View Source [SID1234590599]). Armon Sharei, Ph.D., Chief Executive Officer, will present a corporate overview and the company will be hosting one-on-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PRESENTATION DETAILS

Monday, October 4
Chardan 5th Annual Genetic Medicines Conference
Fireside Chat
4:00-4:25 pm EDT
Webcast

Specific conference webcast details and the company’s corporate overview presentation will be available on the Investors & Media section of the SQZ website. The webcast will be available for 90 days following the presentation.

Signify Health and HealthComp collaborate to develop value-based health benefits

On September 30, 2021 Signify Health (NYSE: SGFY), a leading value-based healthcare platform that leverages advanced analytics, technology and nationwide healthcare provider networks, and HealthComp, the largest independent health benefits administrator in the country, reported a new strategic collaboration to give self-funded employer groups an affordable health benefits package that embeds value-based payments with value-based benefits design (Press release, Signify Health, SEP 30, 2021, https://www.signifyhealth.com/news/signify-health-and-healthcomp-collaborate-to-develop-value-based-health-benefits [SID1234590621]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Having successfully built a value-based care platform to support providers, employers, and health plans who are committed to improving patient outcomes, our collaboration with a leading third-party administrator such as HealthComp opens up new opportunities to drive the transformation away from the broken fee for service model," said Peter Boumenot, Chief Product Officer, Signify Health. "We believe that converging value-based payments with value-based benefit design is essential for all stakeholders at both the individual and the population levels. HealthComp’s proven capabilities will help us bridge this gap for employers across the country who are looking for turnkey solutions that improve costs and outcomes."

"The majority of the employers we work with are looking for new ways to strengthen the alignment of cost, quality and member satisfaction with their benefits offerings," said Justin Tran, Senior Vice President of medical cost management at HealthComp. "By working with Signify Health, we have a unique opportunity to bring together advanced alternative payment models with advanced benefits designs that deliver the clinical and operational excellence needed to address the root causes of suboptimal health outcomes and increasing costs."

Employers are increasingly adopting value-based insurance designs (VBID), which align the appropriate use of high value healthcare services with the engagement of high-performance providers who are accountable for health outcomes. A new white paper published by VBID Health describes how VBID and alternative payment models can be brought together to improve overall health and lower the costs of healthcare delivery and references many of the tools that are available for employers working in collaboration with providers, third-party administrators, and carriers. Early results of similar payment arrangements with Signify Health have shown a promising reduction in both health plan spend and adverse clinical events for members engaged in the program.

The partnership will focus on leveraging Signify Health’s leading capabilities in episode-based financing and high-value provider networks, along with HealthComp’s innovative approach to comprehensive benefits administration and member engagement, to create more affordable, predictable, transparent, and member-focused benefit design. Value-based benefits developed by HealthComp and powered by Signify Health’s value-based payment platform will be offered in select markets across the U.S.

Wall Street Journal: GeoVax Labs Shares Rise 12% After Licensing Deal for Cancer Treatment

On September 30, 2021 GeoVax Labs Inc. shares were up 12% to $4.68 after the company said reported that it entered into an assignment and license agreement with PNP Therapeutics Inc., granting GeoVax exclusive rights to develop and commercialize Gedeptin, a novel patented product for the treatment of solid tumors (Press release, Southern Research Institute, SEP 30, 2021, View Source [SID1234590563]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The biotechnology company said the license provides exclusive worldwide rights to key intellectual property, including Gedeptin patents, know-how, regulatory filings, clinical materials and trademarks.

The patent portfolio covering Gedeptin was originally licensed from the University of Alabama at Birmingham and Southern Research Institute by PNP. Under the License, GeoVax will become the successor to PNP under its license agreement with UAB/SRI.

Detailed financial terms of the transaction weren’t disclosed, but include a combination of upfront payments, milestone fees, and royalties on net sales.

A Phase 1/2 trial, evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma, with tumors accessible for injection and no curable treatment options, is currently enrolling. The initial stage of the study is being funded by the U.S. Food and Drug Administration pursuant to its Orphan Products Clinical Trials Grants Program. The FDA also has granted Gedeptin orphan drug status for the intra-tumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.

Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

On September 30, 2021 Merck, a leading science and technology company, reported a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021 (Press release, Merck & Co, SEP 30, 2021, View Source [SID1234590583]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.

The INTR@PID clinical program sought to validate the potential of the novel mechanism of simultaneously blocking TGF-ß and PD-L1, with the ambition to improve outcomes for patients with difficult-to-treat cancers. Given the extent of the clinical program, Merck will deepen its scientific leadership in the field and interrogate the data leveraging the power of advanced analytics. The important insights this program has yielded about the biology of TGF-β will inform the collective understanding of this pathway.

Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts, comprised of 10 ongoing development programs, aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and head and neck and thoracic cancers. Learn more at View Source

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.